Discovery of small molecule leads in a biotechnology datastream

Drug Discovery Today

Volumn 8, Issue 12, 2003, Pages 545-550

  Gadek, Thomas R ^a   McDowell, Robert S ^b  

^a GENENTECH INC   (United States)

^b Sunesis Pharmaceuticals Inc   (United States)

Author keywords

Drug Discovery; GPIIbIIIa; Integrin; Lead discovery; LFA 1; Peptidomimetic; Pharmaceutical Science; Protein SAR; SAR; Structure activity relationship; Techniques Methods

Indexed keywords

ABCIXIMAB; AGGRESTAT; CYCLOTHREONYLGLUTAMINYLISOLEUCYLASPARTYLSERYLPROLYLASPARAGINYLGLYCINE; CYCLOTYROSYLCYSTEINYLASPARTYLPROLYLCYSTEINE; EPITOPE; EPTIFIBATIDE; GLYCYLARGINYLGLYCYLASPARTYLSERYLPROLINE; INTEGRIN; INTEGRIN ALPHA1BETA2; INTEGRIN ALPHA4BETA7; INTEGRIN LYMPHOCYTE FUNCTIONAL ANTIGEN 1; PEPTIDE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR;

ASTHMA; BIOTECHNOLOGY; CANCER; CLINICAL TRIAL; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL DISEASE; HUMAN; LIGAND BINDING; MULTIPLE SCLEROSIS; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOPOROSIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; X RAY CRYSTALLOGRAPHY;

BIOTECHNOLOGY; DRUG DESIGN; INTEGRINS; LIGANDS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MOLECULAR MIMICRY; PEPTIDES; PHARMACEUTICAL PREPARATIONS; RESEARCH;

EID: 0038802739     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02735-1     Document Type: Review

References (39)

1. Hirschmann R.F. Wermuth C. Foreward to: The Practice of Medicinal Chemistry. 2nd edn:2003;Elsevier.
2. Hillis G.S., MacLeod A.M. Integrins and disease. Clin. Sci. 91:1996;639-650.
3. Vorchheimer D.A., et al. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. J. Am. Med. Assoc. 281:1999;1407-1414.
4. Ockey D.A., Gadek T.R. Inhibitors of protein-protein interactions. Expert Opin. Ther. Pat. 12:2002;393-400.
5. Bodary S.C., et al. Expression of recombinant platelet glycoprotein IIbIIIa results in a functional fibrinogen-binding complex. J. Biol. Chem. 264:1989;18859-18862.
6. Fei D.T.W., et al. RGD-containing peptides inhibit adhesion of 293 cells transfected with GpIIb/IIIa to fibrinogen: comparison to inhibition of platelet aggregation. Blood Coagul. Fibrinolysis. 4:1993;255-262.
7. Barker P.L., et al. Cyclic RGD peptide analogs as antiplatelet antithrombotics. J. Med. Chem. 35:1992;2040-2048.
8. McDowell R.S., et al. From peptide to non-peptide. 2. The de novo design of potent, non-peptidal inhibitors of platelet aggregation based on a benzodiazepinedione scaffold. J. Am. Chem. Soc. 116:1994;5077-5083.
9. Dickfeld T., et al. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thromb. Res. 101:2001;53-64.
10. Furuya K., et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke. 32:2001;2665-2674.
11. Kimura S.R., et al. Dynamical view of the positions of key side chains in protein-protein recognition. Biophys. J. 80:2001;635-642.
12. Pearce K.H. Jr, et al. Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface. Biochemistry. 35:1996;10300-10307.
13. Smith A.B. 3rd, et al. Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones toward the creation of a privileged nonpeptide scaffold. Bioorg. Med. Chem. 7:1999;9-22.
14. Jackson D.Y. Alpha 4 integrin antagonists. Curr. Pharm. Des. 8:2002;1229-1253.
15. Gadek T.R., et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 295:2002;1086-1089.
16. Freidinger R.M. Nonpeptidic ligands for peptide and protein receptors. Curr. Opin. Chem. Biol. 3:1999;395-406.
17. Ripka A.S., Rich D.H. Peptidomimetic design. Curr. Opin. Chem. Biol. 2:1998;441-452.
18. Gadek T.R., Nicholas J.B. Small molecule antagonists of proteins. Biochem. Pharmacol. 65:2003;1-8.
19. Gadek, T.R. and McDowell, R.S. (1996) Controlling the three dimensional display of the RGD adhesive epitope in peptides and nonpeptides. Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, March 24-28, MEDI-235.
20. Quan C., et al. Transfer of a protein binding epitope to a minimal designed peptide. Biopolymers. 47:1998;265-275.
21. Jackson D.Y., et al. Potent α4β1 peptide antagonists as potential anti-inflammatory agents. J. Med. Chem. 40:1997;3359-3368.
22. Fong S., et al. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Its binding motif for α4β7 and role in experimental colitis. Immunol. Res. 16:1997;299-311.
23. McDowell R.S., Gadek T.R. Structural studies of potent constrained RGD peptides. J. Am. Chem. Soc. 114:1992;9245-9253.
24. McDowell R.S., et al. From peptide to non-peptide. 1. The elucidation of a bioactive conformation of the arginine-glycine-aspartic acid recognition sequence. J. Am. Chem. Soc. 116:1994;5069-5076.
25. Xiong J.-P., et al. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science. 296:2002;151-155.
26. Duggan M.E., Hutchinson J.H. Ligands to the integrin receptor αvβ3. Expert Opin. Ther. Pat. 10:2000;1367-1383.
27. Legge G.B., et al. NMR solution structure of the inserted domain of human leukocyte function associated antigen-1. J. Mol. Biol. 295:2000;1251-1264.
28. Fisher K.L., et al. Identification of the binding site in intercellular adhesion molecule 1 for its receptor, leukocyte function-associated antigen 1. Mol. Biol. Cell. 8:1997;501-515.
29. Renz M.E. Structural requirements for adhesion of soluble recombinant murine vascular cell adhesion molecule-1 to alpha 4 beta 1. J. Cell Biol. 125:1994;1395-1406.
30. Nakakura, E.K. et al. (1993) Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion. Transplantation J, 412-417.
31. Gottlieb A., et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42:2000;428-435.
32. Werther W.A., et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 157:1996;4986-4995.
33. Ashkenazi A., Chamow S.W. Immunoadhesins as research tools and therapeutic agents. Curr. Opin. Immunol. 9:1997;195-200.
34. Edwards C.P., et al. Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted domain of leukocyte function-associated antigen-1. J. Biol. Chem. 273:1998;28937-28944.
35. Gadek T.R., et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 295:2002;1086-1089.
36. Liu G. Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin. Ther. Pat. 11:2001;1383-1393.
37. Shimaoka M., et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 112:2003;99-111.
38. Bella J., et al. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4140-4145.
39. Ali, F.E. et al (1997) Pyridine derivatives and analogs useful as vitronectin receptor antagonists. PCT Int. Appl. WO 9724124, p 133.